Form 4: Evolent Health Director Craig Barbarosh Receives Significant RSU Grant

Evolent Health, Inc. Director Craig A. Barbarosh was granted 21,979 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Craig A. Barbarosh, a Director of Evolent Health, Inc. (EVH), acquired 21,979 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• The acquisition was a grant, indicated by a transaction price of $0 per share.
• Following this transaction, Mr. Barbarosh beneficially owns a total of 53,935 shares of Class A Common Stock.
• The RSUs are set to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent upon Mr. Barbarosh's continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It is a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction is part of a standard incentive compensation plan, indicating a structured approach to executive and director remuneration.

Risks

• The vesting of the granted Restricted Stock Units is subject to the reporting person's continued service, meaning the director must remain on the board until the vesting date to receive the shares.

Future Outlook

The Restricted Stock Units granted to Director Craig A. Barbarosh are scheduled to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent on his continued service.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the healthcare technology and services industry, used to incentivize and retain key personnel by linking their compensation to the company's long-term performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across publicly traded companies, including those in the healthcare technology sector like Evolent Health.
• The vesting schedule, tied to continued service and a future date/event, is typical for RSU grants, similar to compensation structures observed at comparable companies such as Teladoc Health (TDOC) or Veeva Systems (VEEV) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Craig A. Barbarosh, a Director of Evolent Health, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units will vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, subject to the director's continued service.

Key Dates

Keywords

Evolent Health, EVH, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant, Corporate Governance